Nurix Therapeutics, Inc. NRIX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $83.98M+54.0% | $54.55M-29.1% | $76.99M+99.3% | $38.63M+29.8% | ||
| $316.9M+43.0% | $221.63M+17.2% | $189.15M+2.5% | $184.5M+58.5% | ||
| $52.74M+14.8% | $45.94M+7.1% | $42.9M+12.9% | $38M+21.8% | ||
| $369.65M+38.1% | $267.58M+15.3% | $232.05M+4.3% | $222.49M+50.7% | ||
| -$285.67M-34.1% | -$213.03M-37.4% | -$155.06M+15.7% | -$183.87M-56.0% | ||
| -340.2%+50.4pp | -390.5%-189pp | -201.4%+275pp | -476%-79.8pp | ||
| -$264.46M-36.6% | -$193.57M-34.5% | -$143.95M+20.2% | -$180.36M-53.9% | ||
| -314.9%+39.9pp | -354.9%-168pp | -187%+280pp | -466.9%-73.0pp | ||
| -$3.05-5.5% | -$2.89-9.1% | -$2.65+28.8% | -$3.72-36.3% | ||
| -$276.93M-35.9% | -$203.71M-38.1% | -$147.53M+17.3% | -$178.46M-54.9% | ||
| -329.8%+43.7pp | -373.4%-182pp | -191.6%+270pp | -462%-74.8pp | ||
| -$285.67M-34.1% | -$213.03M-37.4% | -$155.06M+15.7% | -$183.87M-56.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Nurix Therapeutics, Inc.'s revenue?
- Nurix Therapeutics, Inc. (NRIX) generated $71.8M in revenue over the trailing twelve months, up 27.2% year over year.
- Is Nurix Therapeutics, Inc. profitable?
- Nurix Therapeutics, Inc. is not currently profitable: it reported a net loss of $295.3M over the trailing twelve months, a -411.4% net margin.
- What is Nurix Therapeutics, Inc.'s earnings per share?
- Nurix Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.17.
- Where does Nurix Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
